3 Comments
User's avatar
Olivia Rogers's avatar

I love what you said about the SSVI and addendum. The SSVI needs more work before it is ready for "prime time", although it is already too late for that. And the addendum- I believe this puts an unnecessary burden on both the clinicians and families, who do not need another mandatory piece of paper. I believe ethical hospices are already providing all of the meds, supplies, DME and procedures that are related to the overall terminal condition, and those who are not really should. That language already exists in the election statement. We should be covering virtually all care that is related. But I really love what you said about not being able to control some other things. While we should be asking questions about other appointments, treatments, therapy that the patient is receiving to try to make sure we know all non-hospice spending, sometimes those things happen outside of what we know. Again, ethical hospices are trying to prevent this. I support fraud prevention and oversight, but these broad-sweeping requirements don't seem to get to the heart of what is really wrong.

Christy Whitney's avatar

It’s certainly a conundrum. I get the impetus for sure. In my 35 years as a hospice CEO I used to say we were among those on a short list that did it right. And that was hard. Hard to have contracts with all hospitals etc. for sure for covering appropriate therapy. On the other hand it seems just as bad or worse to discharge every patient that enters acute care. I would say that is a common practice among the more than 50 percent of hospices that report no GIP. The current benefit is tough to have with how today’s medicine is practiced. Pace is certainly more complex but the system makes sense and works. Very challenging. It would take quite a bit to make it all right. Hospice inpatient facilities solve so much of the concurrent billing and inappropriate interventions. Thanks Jim for the insights.

Beth Noyce's avatar

Jim, the mandatory addendum is absolutely the wrong approach.

CMS states, as I paraphrase, in its FY 2020 Hospice Final Rule that because the addendum was ineffective in curbing non-hospice Medicare spending for hospice-enrolled patients, and in fact the spending has increased since the addendum was implemented, CMS wants hospices to use it for everyone.

Hmmm.

Applying an already-proven-as-ineffective tool more broadly does not make sense. Instead, CMS should have instigated an RTP for non-hospice claims for hospice-enrolled patients unless the identified hospice verifies that the service/item/drug is unrelated. CMS has edits on so many other things. Why can't it place an edit on Part-B and Part-D claims filed during hospice enrollment unless they are filed by the attending physician identified on the claim? CMS contractors could then audit such claims to determine if they are truly identified by the hospice as unrelated, and to determine whether such a designation is appropriate for the specific patient.

Anyway, that's my two cents' worth.

Beth